Journal article
Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study
Corina Behrenbruch, Sowmya Prabhakaran, Dilshan Udayasiri, Frederic Hollande, Michael Michael, Ian Hayes, Alexander Heriot, Brett Knowles, Benjamin Thomson
ANZ JOURNAL OF SURGERY | WILEY | Published : 2021
DOI: 10.1111/ans.16613
Abstract
BACKGROUND: There is continued debate about the survival benefit of neoadjuvant chemotherapy (neoCT) in patients with resectable colorectal liver metastases (CRLM). METHODS: In this retrospective cohort study, we included 201 patients with metastatic colorectal cancer who underwent their first CRLM resection and achieved resection of all sites of disease. We compared the overall survival (OS) and progression-free survival (PFS) between patients who received neoCT prior to CRLM resection with those who underwent CRLM upfront. A multivariable Cox proportional hazard regression analysis was performed to adjust for potential confounders. RESULTS: A total of 101 of 201 (51.2%) patients received c..
View full abstract